Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(50%)
Results Posted
50%(1 trials)

Phase Distribution

Ph not_applicable
2
33%
Ph phase_1
1
17%
Ph phase_3
1
17%
Ph early_phase_1
1
17%
Ph phase_2
1
17%

Phase Distribution

2

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
N/ANon-phased studies
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(2)

Detailed Status

Active, not recruiting2
Completed2
Enrolling by invitation1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (16.7%)
Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 31 (16.7%)
N/A2 (33.3%)

Trials by Status

enrolling_by_invitation117%
recruiting117%
active_not_recruiting233%
completed233%

Recent Activity

3 active trials
Showing 5 of 6
active_not_recruitingnot_applicable

Epigallocatechin Gallate (EGCG) as a Flushing Agent During Full Pulpotomy in Mature Permanent Molars With Irreversible Pulpitis

NCT05811403
enrolling_by_invitationphase_3

Oral or Topical Catechins for Radiation Dermatitis

NCT07149506
recruitingphase_2

EGCG for Hepatocellular Carcinoma Chemoprevention

NCT06015022
active_not_recruitingearly_phase_1

Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients

NCT02891538
completednot_applicable

Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients

NCT01744587
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05811403Not Applicable

Epigallocatechin Gallate (EGCG) as a Flushing Agent During Full Pulpotomy in Mature Permanent Molars With Irreversible Pulpitis

Active Not Recruiting
NCT07149506Phase 3

Oral or Topical Catechins for Radiation Dermatitis

Enrolling By Invitation
NCT06015022Phase 2

EGCG for Hepatocellular Carcinoma Chemoprevention

Recruiting
NCT02891538Early Phase 1

Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients

Active Not Recruiting
NCT01744587Not Applicable

Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients

Completed
NCT04177693Phase 1

Pharmacokinetics and Hepatic Safety of EGCG

Completed

All 6 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
6